| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.37% | 47.47% | 87.24% | 85.59% | 94.53% | 94.97% | — | — | — | — | — | — |
| Operating Margin | -712.66% | -507.80% | -190.74% | -213.90% | -122.62% | -108.83% | -34.81% | -40.71% | -97.57% | -29.88% | -42.93% | -36.41% |
| EBITDA Margin | -701.58% | -498.84% | -184.29% | -206.78% | -118.30% | -102.20% | -30.47% | -37.63% | -92.71% | -26.51% | -39.79% | -33.16% |
| Net Margin | 2848.63% | -160.63% | -192.37% | -208.66% | -123.25% | -107.36% | -30.00% | -40.58% | -100.43% | -34.35% | -47.44% | -43.24% |
| Current Ratio | 3.39 | 1.47 | 1.52 | 1.80 | 2.10 | 4.63 | 6.84 | 7.75 | 9.69 | 4.09 | 2.99 | 3.16 |
| Quick Ratio | 3.26 | 1.45 | 1.33 | 1.65 | 1.96 | 4.53 | 6.77 | 7.75 | 9.69 | 4.09 | 2.99 | 3.16 |
| Debt / Equity | — | -0.36 | -0.75 | -53.78 | 0.39 | 0.06 | — | — | — | — | — | — |
| ROE | -1078.81% | 23.20% | 154.74% | 19841.49% | -126.59% | -42.88% | -14.38% | -16.35% | -21.67% | -35.22% | -43.58% | -24.72% |
| ROA | 153.40% | -22.18% | -67.11% | -48.13% | -37.48% | -22.89% | -8.98% | -9.81% | -14.04% | -13.14% | -18.23% | -12.31% |
| Asset Turnover | 0.05 | 0.14 | 0.35 | 0.23 | 0.30 | 0.21 | 0.30 | 0.24 | 0.14 | 0.38 | 0.38 | 0.28 |
| Book Value / Share | -4.21 | -2.05 | -1.89 | -0.02 | 2.48 | 4.91 | 6.18 | 6.29 | 7.98 | 2.79 | 3.26 | 12.82 |
FibroGen, Inc. is a US-based biopharmaceutical company specializing in discovering, developing, and commercializing innovative therapeutics to address serious unmet medical needs. Its lead product, Roxadustat, is an oral small molecule that inhibits hypoxia-inducible factor prolyl hydroxylase, enhancing red blood cell production to treat anemia in chronic kidney disease and chemotherapy-induced anemia. The company’s pipeline includes promising candidates like FG-3246, a first-in-class antibody-drug conjugate targeting CD46, aimed at treating metastatic castration-resistant prostate cancer and other tumors. Established in 1993 and headquartered in San Francisco, California, FibroGen collaborates with major pharmaceutical partners such as Astellas Pharma and AstraZeneca. It plays a significant role in oncology and hematology, leveraging the body's natural pathways to develop treatments for life-threatening conditions, reflecting its commitment to pioneering therapies at the forefront of cancer research.